Arcoxia Approval Status
Arcoxia (etoricoxib) is a selective COX-2 inhibitor for treatment of osteoarthritis.
In April 2007, Merck & Co., Inc. announced the receipt of a Not Approvable Letter from the U.S. Food and Drug Administration (FDA), advising the company that the New Drug Application (NDA) for Arcoxia (etoricoxib) had not been approved.
Development Status and FDA Approval Process for Arcoxia
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.